JOIN US — MAKE YOUR MARK
To learn more about careers with goetzpartners, visit our careers website at:www.joingoetzpartners.com
Curetis N.V. (Euronext: CURE) announced on 7 November, 2018 that it had successfully placed 4,450,000 new ordinary shares with institutional investors at an offer price of EUR 2.00 per share, raising in total gross proceeds of EUR 8.9 million despite challenging market conditions. The funds are expected to be allocated to (i) the commercialization of its Unyvero Platform and LRT Application Cartridge in the U.S., (ii) its European commercialization activities, (iii) working capital requirements, (iv) research and development programs and (v) general corporate purposes.
The new shares were sold by way of a private placement to institutional investors in Europe and the U.S. (including certain existing shareholders) in compliance with applicable securities laws. With the completion of the transaction the number of registered shares of Curetis increased to 20,908,802.
goetzpartners securities Limited was acting as Co-manager in the private placement.
Curetis N.V. is focused on providing innovative solutions for molecular microbiology diagnostics designed to diagnose severe infectious diseases and identify antibiotic resistances in hospitalized patients. Curetis is located in Holzgerlingen, Germany. The Company is listed on Euronext Amsterdam and Euronext Brussels under ISIN NL0011509294 and ticker symbol CURE. Visit www.curetis.com for additional information on Curetis.
Wolf Dornbusch Director Email
Youchen Xin Associate
Erland Sternby Marketing Sales